[Newsmp] In the first half of the year, six listed pharmaceutical and bio companies recorded a net profit of more than KRW 100 billion.
Newsmp tallied the net profit of medicinal and pharmaceutical products manufacturers in the first half and found that three pharmaceutical companies left a net profit of KRW 200 billion units, and three other companies had a net profit of KRW 100 billion units. (Based on separate financial statements)
Moreover, 40 pharmaceutical and bio companies, including the top six, reported more than KRW 10 billion in net profit, of which 22 companies, more than half of them, gathered in the KRW 10 billion range.
Among pharmaceutical and bio companies, Celltrion made a net profit of KRW 299.1 billion during this period. Based on the consolidated financial statements, Celltrion recorded a net profit of KRW 305.3 billion, the only one exceeding KRW 300 billion.
Followed by Celltrion, Samsung Biologics achieved a net profit of KRW 243.1 billion and Humasis of KRW 225.3 billion.
Seegene reported a net profit of over KRW 100 billion with KRW 176.6 billion, Yuhan Corporation with KRW 107.9 billion, and Ilsung Pharmaceutical with KRW 100.4 billion.
SK Bioscience then generated KRW 79.3 billion in net profit, Sugentech KRW 48.9 billion, Chong Kun Dang Pharmaceutical KRW 41.7 billion, Daewoong Pharmaceutical KRW 38.3 billion, DongKook Pharmaceutical KRW 33.6 billion, and Boryung Pharmaceutical KRW 30 billion.
The net profit of Kolmar BNH, Korea United Pharmaceutical, Hanmi Pharmaceutical, GC Pharma, Hugel, and HK inno.N exceeded KRW 20 billion.
Daewon Pharmaceutical, Pharma Research Products, Medy-Tox, Humedix, PCL, Huons, Caregen, Daehan New Pharm, Genolution, Whanin Pharmaceutical, Huons Global, Daihan Pharmaceutical, Biotech Med, JW Pharmaceutical, Hana Pharm, Jetema, Celltrion Pharm, Chong Kun Dang Holdings, T&L, Intron Biotechnology, CTC Bio, and BioPlus generated KRW 10 million units in net profit.
